Compare Dominion Energy Inc (D) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs TG Therapeutics Inc — how do they compare? Dominion Energy Inc trades at $68.19 (market cap $59.90B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Dominion Energy Inc is far larger — about 7.8× TG Therapeutics Inc's market cap, and Dominion Energy Inc pays a 3.92% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| D | TGTX | |
|---|---|---|
Market Cap | $59.90B | $7.64B |
Sector | Utilities | Health |
52-Week High | $71.67 | $59.06 |
52-Week Low | $57.08 | $26.94 |
Enterprise Value | $114.01B | $7.84B |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $67.96, up 1.23% today, with a bearish technical signal and mixed analyst sentiment. Recent Q2 2026 earnings beat estimates ($0.79 vs. $0.681 expected), driven by Virginia utility strength and data center demand, while revenue grew to $16.51B in 2025. The stock faces headwinds from high debt levels and rising operating costs, offset by stable dividends and reaffirmed 2026 guidance.
The outlook is cautious; Dominion benefits from essential service demand and dividend consistency, but valuation appears fair with a P/E of 23.56, and risks include execution on capital projects and regulatory pressures. Analyst consensus leans Hold with a $70.43 price target, suggesting limited near-term upside from current levels.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
